ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /化合物

ピクサントロン

Pixantrone

HCID 134019
反応を作成
印刷
基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
144510-96-3
標準SMILES
NCCNc1ccc(NCCN)c2c1C(=O)c1ccncc1C2=O
InChIKey
PEZPMAYDXJQYRV-UHFFFAOYSA-N
分子式
C17H19N5O2
平均分子量
325.4 g/mol
単同位体質量
325.15387485

概要

Pixantrone is a member of isoquinolines.

名称と識別子

優先名称
Pixantrone
IUPAC
6,9-bis(2-aminoethylamino)benzo[g]isoquinoline-5,10-dione
現地名
ピクサントロン
英語名
Pixantrone
分子式
C17H19N5O2
分子量
325.37

名称と別名

Pixantrone144510-96-36,9-bis(2-aminoethylamino)benzo[g]isoquinoline-5,10-dione6,9-Aea-biqdoPixantronaF5SXN2KNMRBBR-27786,9-bis((2-aminoethyl)amino)benzo[g]isoquinoline-5,10-dioneBBR27786,9-Bis((2-aminoethyl)amino)benzo(g)isoquinoline-5,10-dione6,9-bis[(2-aminoethyl)amino]benzo[g]isoquinoline-5,10-dioneBenz[g]isoquinoline-5,10-dione, 6,9-bis[(2-aminoethyl)amino]-
名称をさらに表示
ピクサントロン6,9-ビス[(2-アミノエチル)アミノ]-5H,10H-ベンゾ[g]イソキノリン-5,10-ジオン6,9-ビス(2-アミノエチルアミノ)-5,10-ジヒドロベンゾ[g]イソキノリン-5,10-ジオンピキサントロン6,9-ビス[(2-アミノエチル)アミノ]ベンゾ[g]イソキノリン-5,10-ジオンCS-1359Pixantrone, BBR 2778BBR 2778Pixantrone diformate salt6,9-Bis[(2-aminoethyl)amino]benz[g]isoquinoline-5,10-dione
DTXSID101627445,8-Bis((2-aminoethyl)amino)-2-aza-anthracene-9,10-dioneBenz(g)isoquinoline-5,10-dione, 6,9-bis((2-aminoethyl)amino)-pixantronum6,9-bis(2-aminoethylamino)benzo(g)isoquinoline-5,10-dioneRefChem:929364DTXCID1085235SID225144373

データベース識別子

CAS
144510-96-3、144675-97-8
PubChem CID
134019
DTXSID
DTXSID10162744
ChEMBL
CHEMBL167731
ChEBI
CHEBI:135945
UNII
F5SXN2KNMR
EC Number
680-661-5
Nikkaji
J580.321G

物性

構造計算による物性

XLogP
1
極性表面積
123 Ų
水素結合供与体数
4
水素結合受容体数
7
回転可能結合数
6
重原子数
24
形式電荷
0
複雑度
472

実験および物理化学的性質

DrugsPharmaceuticals -> Listed in ZINC15

物理化学的性質

融点
173 °C · >173°C (dec.)
沸点
650 · 650.0±55.0 °C(Predicted)
比重(密度)
1.405 · 1.405
貯蔵温度
Refrigerator
溶解性
DMSO(微量)、メタノール(微量)
酸解離定数(Pka)
9.34 · 9.34±0.10(Predicted)
外見
個体
色
ダークブルーからベリーダークブルー

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

GHS分類

GHS Classification · 4 件

Danger

H300 (50%): Fatal if swallowed [Danger Acute toxicity, oral]

P203, P260, P262, P264, P270, P271, P280, P284, P301+P316, P302+P352, P304+P340, P308+P316, P316, P318, P320, P321, P330, P361+P364, P403+P233, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 2 reports by companies from 2 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

危険有害性情報

Hazard Classes and CategoriesAcute Tox. 2 (50%)

安全データ

注意喚起語
警告
危険有害性情報
コード 危険有害性情報 危険有害性クラス 区分 注意喚起語 シンボル P コード H302

化学と産業

薬理情報

ATC Code · 2 件

L - Antineoplastic and immunomodulating agents

QL - Antineoplastic and immunomodulating agents

Protein BindingAnthracyclines, which may be effective second line treatments for NHL have limited use in therapy because of cumulative cardiotoxicity which may result in irreversible damage to cardiac tissue. [2]
Pharmacodynamics · 1 件

Pixantrone has a wide range of antitumor activity, especially in terms of treating leukemias and lymphomas [3]. Pixantrone lacks cardio-toxic effects. It has postulated that his is because of its redox inactivity and lack and inhibition of doxorubicinol formation in human myocardium. [3]

Mechanism of Action · 1 件

Pixantrone is an aza-anthracenedione which acts as a DNA intercalator. By intercalating between DNA, with modest affinity, it stimulates DNA cleavage by topoisomerase II. (Pixantrone acts as a poison to topoisomerase II by stabilizing protein-DNA complexes which are usually transient, giving rise to double stranded DNA breaks.) However, pixantrone is believed to have additional mechanisms of action as its potency does not correlate to the degree of double stranded DNA breaks observed. It has been postulated that this second mechanism may be pixantrone-DNA adduct formation. [1] It is important to note that the formation of a pixtantrone-DNA adduct requires pixantrone activation by formaldehyde. Formadehyde may be generated in vitro by hydrogen peroxide, and is derived by various sources in biological systems. It is present in low levels as a result of normal metabolism, and may be present in elevated levels in some haematolgical malignancies. [1] The formation of pixantrone-DNA adducts is thus feasible, and it is believed that a long pixantrone-DNA adduct half life has the potential to maximize DNA damage. It may do so by enhancing the disruption of DNA replication and transcription, and potentially by encourage apoptosis. [1] In explanation of pixantrones lack of cardiotoxicity, it has been elucidated that pixantrone is structurally similar to mitoxantrone; however, instead of a 5,8-dihydroxyphenyl ring (thought to be responsible for cardiotoxicity) it has a nitrogen heteroatom. This nitrogen heteroatom helps to create additional hydrogen bonding sites amd increases pixantrone interaction with DNA and topoisomerase II. [2] Pixantrone's lack of a hydroquinone is believed to render it resistant to one electron reduction. In contrast, doxorubicin - which contains a hydroquinone - experiences one electron redox cycling and ROS formation via NADH dehydrogenase. [3] Pixantrone also does not bind iron, and thus does not produce ROS by redox cycling between oxidative states of iron, as other anthracyclines do. [2] The first line agent doxorubicin is cardiotoxic, in part, due to its ability to redox activate the superoxide anion and hydrogen peroxide, and form a long-lived secondary alcohol metabolite: doxorubicinol. [3] Clearance of doxorubicin from myocardial tissue is incomplete, and it can be found months or years after the last administration. [3] In doxorubicin treated ex vivo cardiac strips, pixantrone formed an N-dealkylated product that inhibited metabolism of residual doxorubicin into doxorubicinol. Additionally, in ex vivo human myocardial strips (doxorubicin naive, and doxorubicin pretreated) pixantrone showed high cardiac uptake without formation of superoxide anion or hydrogen peroxide. Pixantrones lack of cardiotoxicity is thus attributed to its redox inactivity and inhibition of doxorubicinol formation. [3]

関連反応

8 件
反応記録を作成
HRID 52402 の反応式
HRID 52402生成物として
HRID 269708 の反応式
HRID 269708反応物として
HRID 862158 の反応式
HRID 862158生成物として
HRID 862162 の反応式
HRID 862162生成物として
HRID 862163 の反応式
HRID 862163生成物として
HRID 862164 の反応式
HRID 862164反応物として
HRID 1720233 の反応式
HRID 1720233生成物として
HRID 1720236 の反応式
HRID 1720236生成物として

化合物ノート

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
Biological Half-LifeHalf life ranges from 14.7 to 31.9 hours.
Metabolism/Metabolites · 1 件

Pixantrone does not form secondary alcohol metabolites. [2] Pixantrone hydrolyzes extensively to CT-45886 which is believed to inhibit doxol formation by displacing DOX from the active site of reductases. CT4889 and CT-45890 are also formed.[3]

MeSH Pharmacological Classification · 1 件

Compounds that inhibit the activity of DNA TOPOISOMERASE II. Included in this category are a variety of ANTINEOPLASTIC AGENTS which target the eukaryotic form of topoisomerase II and ANTIBACTERIAL AGENTS which target the prokaryotic form of topoisomerase II.

Absorption, Distribution and Excretion · 4 件

Intravenous administration results in a rapid distribution followed by a slow elimination. [2] In ex vivo myocardial strips, pixantrone is taken up to a higher degree than mitoxantrone. In myocardial strips which are doxorubicin naive pixantrone displays higher uptake than in DOX-loaded myocardial strips. DOX clearance causes membrane effects which may be responsible for this observation. DOX clearance involves rapid passive diffusion through one side of the membrane followed by "flip flop" reorientation of the lipid bilayer. This disorganization of lipids is believed to impair membrane penetration by pixantrone. [3]

Fecally and renally excreted. Urinary elimination of unchanged drug is less than 10%. [2]

9.7-29.7 L/kg. [2]

Plasma clearance is 0.75 - 1.31 L/h/kg. [2]

応用分野 · 2 件

説明In May 2012, pixantrone was approved by the European Commission as a single agent for the treatment of relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL) in adult patients who have failed on at least two previous therapies. Pixantrone (also known as BBR- 2778) is an anthracycline analogue that was specifically designed to address the cardiotoxicity seen in earlier agents by replacement of a 1,4- dihydroxyanthracene-9,10-dione core with a benzoisoquinoline-5,10-dione ring system. Pixantrone inhibits topoisomerase II by intercalation with DNA and is also believed to form covalent adducts with the N-2 amino group of guanine via a formaldehyde aminal formed with the primary amino groups. Pixantrone is less cytotoxic than other anthracycline derivatives, but shows good antitumor activity in vivo in a variety of preclinical tumor models, including leukemia and lymphoma models. Pixantrone also demonstrated significantly reduced cardiotoxicity in preclinical models compared with the anthracyclines doxorubicin and mitroxantrone. Pixantrone was synthesized by Friedel–Crafts reaction of pyridine-3,4-dicarboxylic acid anhydride with 1,4-difluorobenzene to give a ketoacid that was cyclized to the tricyclic core by treatment with fuming sulfuric acid at 140℃. Reaction of the resulting 6,9-difluorobenzoisoquinoline-5-10-dione with ethylenediamine followed by careful pH adjustment and treatment with maleic acid gave pixantrone in good overall yield and purity.

使用Pixantrone is an antineoplastic drug belonging to group of antitumor antibiotics. Pixantrone is an anlogue of Mitoxantrone (M373425) and is just as potent in the treatment of multiple sclerosis with fewer toxic effects on cardiac tissue. Studies suggest that Pixantrone significantly reduces amyloid beta (A beta(1-42)) neurotoxicity, a mechanism implicated in Alzheimer's disease.

上流・下流製品情報

上流原料

Benz[g]isoquinoline-5,10-dione, 6,9-dihydroxy-6,9-ジフルオロベンゾ[G]イソキノリン-5,10-ジオン3,4-ピリジンジカルボン酸無水物エチレンジアミン (無水)シンコメロン酸